Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Liabilities and Shareholders Equity: 2017-2025

Historic Liabilities and Shareholders Equity for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $518.6 million.

  • Cidara Therapeutics' Liabilities and Shareholders Equity rose 219.50% to $518.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 220.46%. This contributed to the annual value of $214.8 million for FY2024, which is 220.45% up from last year.
  • As of Q3 2025, Cidara Therapeutics' Liabilities and Shareholders Equity stood at $518.6 million, which was down 2.93% from $534.3 million recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' Liabilities and Shareholders Equity ranged from a high of $534.3 million in Q2 2025 and a low of $39.4 million during Q2 2022.
  • In the last 3 years, Cidara Therapeutics' Liabilities and Shareholders Equity had a median value of $162.3 million in 2024 and averaged $193.6 million.
  • In the last 5 years, Cidara Therapeutics' Liabilities and Shareholders Equity tumbled by 38.25% in 2022 and then surged by 263.70% in 2025.
  • Over the past 5 years, Cidara Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $75.3 million in 2021, then slumped by 36.96% to $47.5 million in 2022, then spiked by 41.15% to $67.0 million in 2023, then soared by 220.45% to $214.8 million in 2024, then surged by 219.50% to $518.6 million in 2025.
  • Its Liabilities and Shareholders Equity was $518.6 million in Q3 2025, compared to $534.3 million in Q2 2025 and $191.7 million in Q1 2025.